Related references
Note: Only part of the references are listed.Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
G. Caleb Alexander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Open Peer Commentary to Failure to demonstrate efficacy of aducanumab: An analysis of the EMRGE and ENGAGE Trials as reported by Biogen December 2019
Marwan Noel Sabbagh et al.
ALZHEIMERS & DEMENTIA (2021)
What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study
Julie Watson et al.
HEALTH EXPECTATIONS (2019)
The rights of precision drug development for Alzheimer's disease
Jeffrey Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Joseph W. Arndt et al.
SCIENTIFIC REPORTS (2018)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Share Paper
